![Genetic research and Biotech science](/mediaassets/images/corporate/acquisition.jpg?w=1920&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=5438EE99D1AA11AD0E545FC7C4C962CD)
Acquisitions
![2023 results](/mediaassets/images/corporate/image.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=FF8BF9BA99FA36CFFC0C907ECC687E42)
Full year results announcement 2023
![Louisa Burdett](/mediaassets/images/corporate/about-us/board-and-exec/louisa-burdett-2.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=ED5145B2BAE5825814D6D36687685D5D)
Directorate change and Full Year 2023 outlook confirmed
![China groundbreak](/mediaassets/images/corporate/locations/china-groundbreak.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=F0E89CB48FABF94426AFBB721190D447)
Croda breaks ground at new Consumer Care production facility in China
![skin care](/mediaassets/images/corporate/products-and-markets/skin-care.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=F8017A518D1653D00490CA063E66102C)
Croda successfully completes acquisition of Solus Biotech
![](/mediaassets/images/corporate/investors/dalmation-2.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=7D7F8D8C4B78296EEC478C87D67913F0)
Croda expands Iberchems fragrances offering with the acquisition of Parfex
![](/mediaassets/images/corporate/investors/alban-muller-banner-image.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=E1FF7E7E0091C6895CA86C83F03891A7)
Acquisition of Alban Muller
![Female Perfumer in laboratory](/mediaassets/images/corporate/our-brands/iberchem/perfumer3.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=A104881DE142A1E71151C8C7D1047819)
Acquisition of Iberchem expands reach into high growth fragrances market
![](/mediaassets/images/corporate/investors/hero-case-study-shutterstock-1183890526.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=CC72B63F254FC61EB006339B89CC3993)
Strengthening Life Sciences with the acquisition of Avanti Polar Lipids
![](/mediaassets/images/corporate/investors/entekno.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=8645C0032FE2C914C27797838A2F3B71)
Strategic investment Entekno Materials
![Croda employee in lab denmark](/mediaassets/images/corporate/about-us/croda-denmark-vaccine-adjuvant-specialists-acquisition-of-biosector-brenntag-biosector-in-2019.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=B999DD2826ACE92A64FC280559F2D5E1)
Acquisition of global vaccine adjuvant specialist
![](/mediaassets/images/corporate/investors/sisaf.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=4699AB29AC48B122595E4C7DDE5605FF)
Acquisition of global vaccine adjuvant specialist
![](/mediaassets/images/corporate/investors/plant-impact-crop-screen-testing.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=60450DF6954FAB42B2903F4B684B1CA7)
Croda acquired crop enhancement company Plant Impact
![Nautilus Bioscience](/mediaassets/images/corporate/our-brands/nautilus/nautilus-bioscience.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=E09499C3C2613F56A9CFFA97DA843679)
Croda acquires marine biotechnology specialists Nautilus
![Enza Biotech](/mediaassets/images/corporate/news/enza-biotech.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=7FDF2AB2EB50051828F4D2AE1A6534B7)
Croda acquires research enterprise Enza Biotech
![](/mediaassets/images/corporate/innovation/green-manufacturing.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=845F067BB8EF0E87F66628D7C2D61FED)
Croda acquires Inventiva, encapsulation and delivery system technology
![](/mediaassets/images/corporate/investors/microplastc-free-4.jpg?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=06B1576FC2CC3C158CC8A6974B3BC11E)
Croda acquires innovative seed enhancement company Incotec
![Female Perfumer in laboratory](/mediaassets/images/corporate/our-brands/iberchem/perfumer3.jpg?h=918&iar=0&w=768&la=en-GB&hash=83B28F4AE4F52A0F559312AB39DCD09F)
Case study: New frontiers in fragrance and flavours - Iberchem, Croda - sustainability, ethics and anti-corruption
Croda acquired international fragrances and flavours company Iberchem in 2020, the largest acquisition in our history and a major move into a market strongly aligned with our business.
Described as being ‘at the crossroads of science and creativity’, Iberchem brought fragrances into our portfolio, enabling us to create a one-stop-shop for our Personal Care and Home Care customers. As sensory considerations become more important to consumers, fragrances are reported as a primary purchase driver in personal care and household products. They are also a known emotional trigger, with the power to boost wellbeing.
Our drive to advance the sustainability of practices in the flavours and fragrances sector is shared by our colleagues at Iberchem. For example, 100% of the water used by Iberchem’s production plant in Murcia is recycled by an Authorised Waste Management Company. A solar photovoltaic system was also installed in 2020 that will avoid the annual emission of more than 171 tonnes of CO2 annually.
Our drive to integrate our acquired businesses into our wider ethics and compliance programme is also shared by our colleagues at Iberchem. For example, Iberchem has hired a dedicated compliance officer to oversee the integration of Iberchem into Croda’s wider ethics and anti-corruption programme and has adopted Croda’s Speak Up reporting line.
Read more about our Ethics and Anti-Corruption Programme here
![Biosector](/mediaassets/images/corporate/sustainability/croda-denmark-vaccine-adjuvant-specialists-acquisition-of-biosector-brenntag-biosector-in-2019.jpg?h=511&iar=0&w=768&la=en-GB&hash=CBEC380969AEBD5B9B7BAE591B5F996A)
Case Study: Advancing the efficacy and impact of vaccines - innovation in adjuvants
A leading specialist in this field, our adjuvant technologies are now advancing the efficacy and impact of vaccines to target diseases in well-known areas, such as COVID-19 and conjugate pneumococcal vaccines, alongside developments in more difficult areas such as HIV/AIDS, malaria, hepatitis B and tuberculosis. Our adjuvant pipeline includes vaccines for diseases highlighted by the World Health Organisation (WHO) as key to achieving the United Nations’ Sustainable Development Goal 3 for Good Health and Wellbeing. Advancing our ability to contribute to WHO-listed pipeline vaccines directly contributes to our ambition to become People Positive by 2030.